Insider · CIK 0001684015

Borges Luis

Reports to the SEC for 3 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001684015

Forms 4 and 5

Insider transactions

25 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-04-01	MGXMetagenomi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+291K sh	—	—	291,450
2024-04-01	MGXMetagenomi Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+69.3K sh	—	—	69,316
2023-04-03	IPSCCentury Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+7,452 sh	$1.03	+$7,675.56	256,535
2023-04-03	IPSCCentury Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−7,452 sh	—	—	0
2023-03-23	IPSCCentury Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−221K sh	—	—	7,452
2023-03-23	IPSCCentury Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+221K sh	$1.03	+$228K	264,680
2023-03-23	IPSCCentury Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−15.6K sh	$3.55	−$55.4K	249,083
2023-03-22	IPSCCentury Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+65.7K sh	$1.03	+$67.7K	109,448
2023-03-22	IPSCCentury Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−65.7K sh	$3.72	−$245K	43,750
2023-03-22	IPSCCentury Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−65.7K sh	—	—	228,382
2023-03-21	IPSCCentury Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+63.6K sh	$1.03	+$65.5K	107,366
2023-03-21	IPSCCentury Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−63.6K sh	—	—	294,080
2023-03-21	IPSCCentury Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−63.6K sh	$3.77	−$240K	43,750
2023-02-02	IPSCCentury Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+21.9K sh	—	—	43,750
2023-02-02	IPSCCentury Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+131K sh	—	—	131,250
2023-02-02	IPSCCentury Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+131K sh	—	—	131,250
2023-02-02	IPSCCentury Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+21.9K sh	—	—	21,875
2022-01-25	IPSCCentury Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+105K sh	—	—	105,000
2017-03-01	FIVE PRIME THERAPEUTICS, INC.F Tax Payment	SVP, Research	FTax Payment	−18.1K sh	$44.77	−$810K	64,888
2017-02-07	FIVE PRIME THERAPEUTICS, INC.A Award	SVP, Research	AAward	+7,031 sh	—	—	82,972
2017-02-07	FIVE PRIME THERAPEUTICS, INC.Employee Stock Option (right to buy)A Award	SVP, Research	AAward	+25K sh	—	—	25,000
2017-02-07	FIVE PRIME THERAPEUTICS, INC.A Award	SVP, Research	AAward	+5,625 sh	—	—	75,941
2017-01-03	FIVE PRIME THERAPEUTICS, INC.F Tax Payment	SVP, Research	FTax Payment	−1,306 sh	$48.60	−$63.5K	70,316
2016-09-08	FIVE PRIME THERAPEUTICS, INC.Employee Stock Option (right to buy)A Award	SVP, Research	AAward	+25K sh	—	—	25,000
2016-09-08	FIVE PRIME THERAPEUTICS, INC.A Award	SVP, Research	AAward	+5,000 sh	—	—	71,622

Recent filings

Accepted (ET)
Apr 34
Borges Luis0000950170-24-041551
SEC(opens sec.gov)
Apr 54
Borges Luis0001062993-23-008770
SEC(opens sec.gov)
Mar 234
Borges Luis0001062993-23-007574
SEC(opens sec.gov)
Feb 64
Borges Luis0001062993-23-002309
SEC(opens sec.gov)
Jan 274
Borges Luis0001062993-22-001688
SEC(opens sec.gov)
Mar 34
FIVE PRIME THERAPEUTICS INC0001209191-17-017109
SEC(opens sec.gov)
Feb 94
FIVE PRIME THERAPEUTICS INC0001209191-17-009276
SEC(opens sec.gov)

Companies

Address

TWO CORPORATE DRIVE

SOUTH SAN FRANCISCO, CA, 94080